Appeals Court Supports Patent Board Flexibility In Ethicon Case
This article was originally published in The Gray Sheet
Executive Summary
Ethicon argued that a US Patent and Trademark Board policy allowing the same panel to decide whether to accept a patent challenge for review and issue a final ruling on its validity violates due process. A split Federal Circuit panel disagreed and supported the patent board’s finding that Ethicon’s surgical staple patent is invalid.
You may also be interested in...
High Court Won’t Hear Covidien Patent Appeal
The company had asked the Supreme Court to hear arguments to restore a $176 million patent infringement judgment against Ethicon. A lower court voided the award because Ethicon developed a prototype before Covidien’s patents were filed.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.